Literature DB >> 30481622

Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors.

Joshua D Bernstock1, Zachary Wright2, Asim K Bag3, Florian Gessler4, George Yancey Gillespie5, James M Markert5, Gregory K Friedman6, James M Johnston2.   

Abstract

OBJECTIVE: The engineered herpes simplex virus-1 G207, is a promising therapeutic option for central nervous system tumors. The first-ever pediatric phase 1 trial of continuous-infusion delivery of G207 via intratumoral catheters for recurrent or progressive malignant brain tumors is ongoing. In this article, we describe surgical techniques for the accurate placement of catheters in multiple supratentorial locations and perioperative complications associated with such procedures.
METHODS: A prospective study of G207 in children with recurrent malignant supratentorial tumors is ongoing. Preoperative stereotactic protocol magnetic resonance imaging was performed, and catheter trajectories planned using StealthStation planning software. Children underwent placement of 3-4 silastic catheters using a small incision burr hole and the Vertek system. Patients had a preinfusion computed tomography scan to confirm correct placement of catheters.
RESULTS: Six children underwent implantation of 3-4 catheters. Locations of catheter placement included frontal, temporal, parietal, and occipital lobes, and the insula and thalamus. There were no clinically significant perioperative complications. Postoperative computed tomography scans coupled with preoperative MRI scans demonstrated accurate placement of 21 of 22 catheters, with 1 misplaced catheter pulled back to an optimal location at the bedside. One patient had hemorrhage along the catheter tract that was clinically asymptomatic. Another patient had cerebrospinal fluid leak from a biopsy incision 9 days after surgery that was oversewn without complication.
CONCLUSIONS: The placement of multiple intratumoral catheters in pediatric patients with supratentorial tumors via frameless stereotactic techniques is feasible and safe. Intratumoral catheters provide a potentially effective route for the delivery of G207 and may be employed in other trials utilizing oncolytic virotherapy for brain tumors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Oncolytic virotherapy; Pediatric brain tumors; Recurrent brain tumors; Stereotactic surgery

Mesh:

Year:  2018        PMID: 30481622      PMCID: PMC6929209          DOI: 10.1016/j.wneu.2018.11.122

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  35 in total

1.  Frameless localization for functional neurosurgical procedures: a preliminary accuracy study.

Authors:  Jaimie M Henderson
Journal:  Stereotact Funct Neurosurg       Date:  2004-10-04       Impact factor: 1.875

2.  Precision of navigated stereotactic probe implantation into the brainstem.

Authors:  Henrik Giese; Karl-Titus Hoffmann; Andreas Winkelmann; Florian Stockhammer; George I Jallo; Ulrich-W Thomale
Journal:  J Neurosurg Pediatr       Date:  2010-04       Impact factor: 2.375

Review 3.  Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors.

Authors:  Amar Gajjar; Barry Pizer
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

4.  Minimizing brain shift during functional neurosurgical procedures - a simple burr hole technique that can decrease CSF loss and intracranial air.

Authors:  V A Coenen; A Abdel-Rahman; J McMaster; N Bogod; C R Honey
Journal:  Cent Eur Neurosurg       Date:  2011-07-07

5.  Frameless stereotactic procedures in pediatric patients: safety and diagnostic efficacy.

Authors:  Mary G Parreño; Xiao Bo; Okezie O Kanu; Shlomi Constantini; Andrew A Kanner
Journal:  Childs Nerv Syst       Date:  2011-06-10       Impact factor: 1.475

6.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

7.  Accuracy of VarioGuide Frameless Stereotactic System Against Frame-Based Stereotaxy: Prospective, Randomized, Single-Center Study.

Authors:  Ondrej Bradac; Anna Steklacova; Katerina Nebrenska; Jiri Vrana; Patricia de Lacy; Vladimir Benes
Journal:  World Neurosurg       Date:  2017-04-25       Impact factor: 2.104

8.  Cerebrospinal fluid disturbances after 381 consecutive craniotomies for intracranial tumors in pediatric patients.

Authors:  Sayied Abdol Mohieb Hosainey; Benjamin Lassen; Eirik Helseth; Torstein R Meling
Journal:  J Neurosurg Pediatr       Date:  2014-10-17       Impact factor: 2.375

9.  Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage.

Authors:  J Chou; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

10.  Experimental therapy of human glioma by means of a genetically engineered virus mutant.

Authors:  R L Martuza; A Malick; J M Markert; K L Ruffner; D M Coen
Journal:  Science       Date:  1991-05-10       Impact factor: 47.728

View more
  6 in total

Review 1.  Multiple strategies to improve the therapeutic efficacy of oncolytic herpes simplex virus in the treatment of glioblastoma.

Authors:  Zhengjun Zhou; Junjie Tian; Wenyan Zhang; Wei Xiang; Yang Ming; Ligang Chen; Jie Zhou
Journal:  Oncol Lett       Date:  2021-05-03       Impact factor: 2.967

2.  First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors.

Authors:  David Ruano; José A López-Martín; Lucas Moreno; Álvaro Lassaletta; Francisco Bautista; Maitane Andión; Carmen Hernández; África González-Murillo; Gustavo Melen; Ramón Alemany; Luis Madero; Javier García-Castro; Manuel Ramírez
Journal:  Mol Ther       Date:  2020-01-21       Impact factor: 11.454

3.  Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.

Authors:  Joshua D Bernstock; Asim K Bag; John Fiveash; Kara Kachurak; Galal Elsayed; Gustavo Chagoya; Florian Gessler; Pablo A Valdes; Avi Madan-Swain; Richard Whitley; James M Markert; G Yancey Gillespie; James M Johnston; Gregory K Friedman
Journal:  Hum Gene Ther       Date:  2020-08-17       Impact factor: 5.695

Review 4.  Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance.

Authors:  Stacie K Totsch; Charles Schlappi; Kyung-Don Kang; Andrew S Ishizuka; Geoffrey M Lynn; Brandon Fox; Elizabeth A Beierle; Richard J Whitley; James M Markert; G Yancey Gillespie; Joshua D Bernstock; Gregory K Friedman
Journal:  Oncogene       Date:  2019-07-09       Impact factor: 8.756

5.  Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition.

Authors:  Yoshihiro Otani; Ji Young Yoo; Samantha Chao; Joseph Liu; Alena Cristina Jaime-Ramirez; Tae Jin Lee; Brian Hurwitz; Yuanqing Yan; Hongsheng Dai; Joseph C Glorioso; Michael A Caligiuri; Jianhua Yu; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2020-03-05       Impact factor: 12.531

6.  A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.

Authors:  Joshua D Bernstock; Nunzio Vicario; Li Rong; Pablo A Valdes; Bryan D Choi; Jason A Chen; Daniel DiToro; Diana S Osorio; Kara Kachurak; Florian Gessler; James M Johnston; T Prescott Atkinson; Richard J Whitley; Asim K Bag; G Yancey Gillespie; James M Markert; Dragan Maric; Gregory K Friedman
Journal:  Oncoimmunology       Date:  2019-10-21       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.